FDA chief admits he oversold COVID-19 plasma effectiveness

Trump and Dr. Stephen Hahn
(Image credit: Pete Marovich/Getty Images)

Scientists were immediately skeptical when Food and Drug Administration chief Stephen Hahn, Health Secretary Alex Azar, and President Trump announced Sunday evening that the FDA had given emergency use approval for plasma from recovered COVID-19 patients, right before the Republican National Convention. And they were baffled when all three men claimed plasma had been shown to reduce deaths by 35 percent, meaning, Hanh said, that 35 out of 100 COVID-19 patients "would have been saved because of the administration of plasma."

That impressive statistic was evidently excavated from a small subsample of a large observational study from the Mayo Clinic, and it doesn't mean what Trump, Azar, and Hahn said it does. Hahn and whoever else came up with the number "appeared to have mixed up absolute risk and relative risk, which are basic concepts in economics and in the presentation of data from clinical trials," The Washington Post notes, explaining:

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.